
Actively managed fund
Janus Henderson Hrzn Biotec H2 USD
- ISIN
- LU1897414485
- Category
- Sector Equity Biotechnology
- Minimum investment
- 7,500 USD
How good is this fund, really?
See the rating in the appAbout Janus Henderson Hrzn Biotec H2 USD
Biotechnology is the single sector of Janus Henderson Horizon Biotechnology Fund, a Luxembourg SICAV sub-fund managed by Janus Henderson Investors Europe S.A. At least 80% of assets go into biotech or biotech-related shares worldwide, smaller companies included, with a possible tilt to firms whose products are still in development. The team targets innovative companies tackling high unmet medical needs that trade well below estimated intrinsic value, using statistical models of clinical success plus physician surveys, prescription models and scenario analysis. The aim: beat the NASDAQ Biotechnology Total Return Index by 2% a year, before charges, over any five years. This US dollar H2 class, launched in December 2018, accumulates income and charges 1.24% a year. Risk: 6 of 7. Recommended horizon: five years or more.
Watch this fund for free Add Janus Henderson Hrzn Biotec H2 USD to your watchlist in the PowerFunds app and we tell you when it falls behind the rest of its category.
Watch the fund for freeWhere to buy Janus Henderson Hrzn Biotec H2 USD — platforms and fees
Sold on one platform we follow.
-
AJ Bell Annual fee: See the platformGo to AJ Bell ↗
Janus Henderson Hrzn Biotec H2 USD — its category
Sector Equity Biotechnology — PowerFunds rates 55 funds in this category every month.
Biotechnology funds →Other funds
- Franklin Biotechnology Discv Z(acc)GBP
- Global X Genomics & Biotech ETF USD Acc
- International Biotechnology Ord
- Invesco NASDAQ Biotech ETF
- iShares Nasdaq US Biotech ETF USD Acc
- iShares Nasdaq US Biotech ETF USD Dist
- JPM Thmtcs Gentc Thrps C dist GBP
- L&G Pharma Breakthrough ETF
- LS ARK Genomic Revolution Trkr ETP Scs
- Pictet-Biotech I dy GBP
- Polar Capital Biotech I Inc
- RTW Biotech Opportunities Ord